Rise for Rare - Black Women's Health Imperative

Travere Therapeutics Supports Rare Disease Diversity Coalition’s “Rise for Rare” Campaign

November 18, 2020 - Today, the Black Women’s Health Imperative (BWHI) announced the launch of a comprehensive multi-channel campaign entitled RISE for Rare (#riseforrare). 
Travere Circle Logo

Retrophin Announces Corporate Name Change to Travere Therapeutics, Inc.

SAN DIEGO, November 16, 2020 – Retrophin Inc., (NASDAQ: RTRX) today announced that the company has changed its global corporate name to Travere Therapeutics, Inc. Read the press release >
Lightbulb icon with Kidneys

Rare Kidney Disease Patients Deserve Better

Help us improve the lives of families living with these conditions by downloading our new community call to action at rarekidneyrevolution.com.
Travere Circle Logo

Travere Therapeutics: Our Brand Story

We come to work every day to do something extraordinary that can make a difference in the lives of the patients we serve. This is the core of who we are at Travere Therapeutics.
Kevin, living with FSGS

Meet Kevin

A tale of racial bias that delayed a diagnosis.
Travere Circle Logo

Retrophin Completes Acquisition of Orphan Technologies

SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the completion of its previously announced acquisition of Orphan Technologies Limited, a privately held, clinical-stage biopharmaceutical company focused on the development of product candidate OT-58 for the treatment of classical homocystinuria (HCU). Read the press release >
A boy and his parents seated outside

Meet Matthew

Author, composer and life-long learner, Matthew lives with peroxisome biogenesis disorder-Zellweger spectrum disorder (PBD-ZSD).
Smiling young adult who shares her story about living with rare disease

Meet Lindsey

At the 2019 ERA-EDTA Congress in Budapest, the company hosted a panel discussion led by people living with rare glomerular disease. Lindsay, a 17-year-old scholar, athlete and musician, shared about her journey with focal segmental glomerulosclerosis (FSGS).
Travere Circle Logo

Retrophin Reports Third Quarter 2020 Financial Results

SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today reported its third quarter 2020 financial results and provided a corporate update. Read the press release >
Travere Circle Logo

Retrophin Announces Agreement to Acquire Orphan Technologies

SAN DIEGO, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it has entered into a definitive agreement to acquire Orphan Technologies Limited, a privately held, clinical-stage biopharmaceutical company focused on the development of product candidate OT-58 for the treatment of classical homocystinuria (HCU). Read the press release >